Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.

Alyssa GaiettoJohn C PanettaJennifer L PauleyMary V RellingRaul RibeiroMatthew J EhrhardtChing-Hon PuiHiroto InabaHope D Swanson

Published in: Cancer chemotherapy and pharmacology (2024)

OmR were able to be safely placed and administer intraventricular methotrexate with and without boost doses in patients from 7 days to 22 years old. Boosting strategies are predicted to increase CSF methotrexate concentrations ≥ 1 µM for 72 h.

Keyphrases

end stage renal disease
high dose
newly diagnosed
chronic kidney disease
healthcare
young adults
prognostic factors
peritoneal dialysis
emergency department
patient reported outcomes
acute care
drug induced